Article: Nicotinamide Riboside Reduces Chemotherapy-Induced Eye and Body Hypersensitivity: Preclinical Findings

PrevNext
Neurological Health Neuropathy Preclinical Sensory (Auditory/Optical)

Nicotinamide Riboside Reduces Chemotherapy-Induced Eye and Body Hypersensitivity: Preclinical Findings

Synopsis

Chemotherapy often causes dry eye and nerve pain, which may be due to nerve damage. This study treated rats given the chemotherapy drug paclitaxel with nicotinamide riboside (NR). Paclitaxel caused eye sensitivity to touch and certain chemicals, increased tear production, and caused nerve pain in the hind paws. NR treatment reduced eye and paw sensitivity but did not affect tear production or nerve loss. These results suggest NR can relieve some chemotherapy-induced nerve pain without restoring lost nerve fibers, and this rat model may help study chemotherapy-related eye discomfort.

Journal

Investigative Ophthalmology & Visual Science

Share

Read more

Digestive/Gut Health

Nicotinamide Riboside Alters Gut Microbiota to Reduce Weight Gain from High-Fat Diet in Mice: Preclinical Findings

SynopsisThe gut microbiome influences energy balance and obesity risk. Nicotinamide riboside (NR), a vitamin B3 form and NAD+ precursor, can reduce weight gain and increase energy use in obese mice...

Read more
Intravenous

Effects of Intravenous Nicotinamide Riboside on Muscle NAD+: Preclinical Findings

Synopsis Although nicotinamide riboside (NR)—a common NAD+ booster—is believed to enhance energy metabolism, clinical studies have shown little effect on muscle function or insulin sensitivity. To...

Read more